WINNING THE BATTLE AGAINST ENDOTOXIC SEPTIC SHOCK
The first theranostic: EAA™ & Toraymyxin™
Media
Spectral combining diagnostics with targeted therapy in novel approach to septic shock.
BioTuesdays, November 12, 2024
READ MORE...
Endotoxic Septic Shock & Precision Medicine
Sepsis is a life-threatening condition caused by the body’s overwhelming response to bacterial components like endotoxin. It remains a major global health challenge, affecting millions each year. If not recognized and treated quickly, sepsis can lead to multiple organ failure, shock, and even death. Importantly, endotoxic septic shock (ESS) is the most malignant form of sepsis with a mortality rate in excess of 50%.
At Spectral Medical Inc., we are committed to fighting endotoxic septic shock with our unique theranostic approach. This strategy combines two critical components: the EAA™ Endotoxin Activity Assay, which enables rapid detection of endotoxin activity, and Toraymyxin™ PMX extracorporeal hemoadsorption therapy, designed to remove endotoxins directly from the bloodstream.
Precision Medicine in Action: The Tigris Trial
Our targeted approach to endotoxic septic shock is demonstrated through the Tigris trial, a pivotal clinical study evaluating PMX therapy for patients with ESS. Our recently announced topline results showed that PMX met its prespecified primary endpoint for 28-day mortality, with a posterior probability of benefit of 95.3%. Observed 28-day mortality in the intention-to-treat cohort was 38.7% with PMX versus 45.1% with standard of care, an absolute difference of 6.4%. The severity-adjusted posterior odds ratio was 0.67 [0.39-1.08] using the Bayesian analysis.
The key secondary endpoint, 90-day mortality, demonstrated even more substantial benefit, with a posterior probability of benefit exceeding 99%, an adjusted odds ratio of 0.54 [0.32-0.87], and a number needed to treat (NNT) of 8.1 to save one life at 90 days. These results highlight the potential of Targeted Rapid Endotoxin Adsorption (TREA) to guide precision, data-driven therapy in the ICU. By identifying patients most likely to benefit, clinicians can deliver interventions that directly address the underlying cause of septic shock, moving beyond generalized treatment protocols. Read the full press release here.
Unite for Sepsis Symposium
Spectral is proud to sponsor the upcoming Unite for Sepsis Symposium, taking place September 8–9 in Chicago!
This unique, in-person event will gather an extraordinary community of clinicians, researchers, investors, regulators, innovators, and advocates, all working together to change the future of sepsis care.
Unite for Sepsis is more than a symposium; it’s a collaborative movement focused on transforming the way we prevent, diagnose, and treat sepsis to save lives and limbs.
🔗 Learn more and register today at UniteforSepsis.org
Personalizing Sepsis Treatment
We’re excited to announce that Debra Foster, Clinical Consultant at Spectral Medical, will be participating in the upcoming Unite for Sepsis Symposium, taking place September 8–9 in Chicago.
Debra will be contributing to the session titled “Personalizing Sepsis Treatment” on Day 1 at 4:15 PM CT, a timely discussion on how individualized approaches may support earlier intervention and improved outcomes in sepsis care.
This session is part of a broader effort to bring together clinicians, researchers, innovators, and policymakers to advance the prevention, diagnosis, and treatment of sepsis.
🔗 Learn more and register today at UniteforSepsis.org
Latest News
Spectral Medical Inc. Files Base Shelf Prospectus and Revised AIF
TORONTO, Canada – September 29, 2025 - Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock,...
Spectral Medical Announces Publication of EDEN Observational Study
New Study Strengthens Rationale for Spectral’s PMX Therapy by Defining Endotoxic Septic Shock (ESS) as the Highest-Risk Patient Group TORONTO, Canada – September 16, 2025 - Spectral Medical Inc....
Spectral Medical Sponsors Unite for Sepsis Symposium, Chicago September 8 – 9, 2025
Company to present at session titled “Personalizing Sepsis Treatment” TORONTO, Canada – September 8, 2025 - Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic...
Investor Updates
August 2025 Investor Update
Tigris Trial Topline Results Call Replay
Events
43rd Vicenza Course
AKI–CRRT–EBPT and Critical Care Nephrology
Session: Sepsis and Sepsis-Associated AKI
Presentation: Endotoxin in Sepsis-Associated AKI: Tigris Update
presented by John Kellum, MD, MCCM
Wednesday, June 25th at 11:00
Room Tiziano A, Vicenza Convention Centre
43rd Vicenza Course
AKI–CRRT–EBPT and Critical Care Nephrology
Session: Extracorporeal Therapeutic Options in ICU
Presentation: Managing Endotoxemia with Hemoadsorption
presented by John Kellum, MD, MCCM
Wednesday, June 25th at 16:00
Room Tiziano A, Vicenza Convention Centre
asn - aki 2025
American Society of Nephrology.
Acute Kidney Injury: From Bench to Bedside
Use of Biomarkers in interventional trials for Sepsis and AKI
presented by John Kellum, MD, MCCM
Monday, May 5, 2025 @ 10:20 am – 12:40 pm
Lansdowne Resort, Leesburg, VA
Watch the Replay
Endotoxin, The Phantom Menace of Sepsis
Sepsis Alliance Institute Sponsor Innovation Webinar:
Debra Foster, BSc
Mark A. Tidswell, MD, Professor of Medicine,
UMASS Chan Medical School – Baystate
Thursday October 3, 2024 @ 11am PT | 2pm ET
What part does endotoxin play in the etiology of sepsis and septic shock? This sponsored webinar will describe the human response to elevated levels of endotoxin, both as an adaptive immune response and also as a trigger of sepsis. The ability to measure endotoxin activity in the bloodstream allows clinicians to uncloak its true prevalence and closely examine when endotoxin plays a role in sepsis. Can targeting endotoxin removal be a successful treatment modality for sepsis? Tune in to this webinar to learn more.
Waking up to Endotoxemic Septic Shock
CRRT Conference Breakfast Symposium
Waking up to Endotoxemic Septic Shock. What do you need to be ready?
Wednesday March 13, 2024
San Diego, CA
Moderators: John Kellum and Debra Foster
Diagnosing ESS in the real world – Danielle Davison, George Washington University
Treating ESS in the real world – Javier Neyra, University of Alabama
Implementing PMX hemoadsorption at the bedside – Johann Chang, (Spectral), Tara Morgan-Gray, (Colorado Springs)
Advancing Therapeutic Options for Sepsis and Endotoxic Septic Shock
Featured on The Balancing Act on Lifetime TV.